A Phase 2, Open-Label Dose-Finding Study to Evaluate the Safety, Efficacy, and Tolerability of Multiple Subcutaneous Doses of rAvPAL-PEG in Subjects with PKU" and "Long-term Extension of a Phase 2, Open-Label Dose-Finding Study to Evaluate the Safety, E
|Effective start/end date||4/6/09 → 12/31/14|
- BIOMARIN PHARMACEUTICAL, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.